MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

12,5 mg diclofenac K film coated immediate release tablets (OTC)

APR Applied Pharma Research S.A.
12,5 mg diclofenac K film coated immediate release tablets (OTC)

Full description

Our proprietary formulation in tablets has the main following marketing claims compared to the main diclofenac based OTC competitor Voltadol marketed by Novartis Consumer Health:

- immediate release profile (Cmax. in 21 min. compared to 29 min.)

- regularity of absorption (reduced standard deviation)

- Cost competitive manufacturing process (dry mixing for direct compression)

The product is been recently approved in Germany (November 2006) and it is about to be launched in this country; APR is currently in the process of starting a MRP in order to extend the German approval in the other EU countries. An EU Standard CTD Dossier is also available for registration of the product in countries outside EU. Finally the product is under final registration in Switzerland.

Development status

Registered

Patent information

The patent has been granted in the following countries: Europe, South Africa, New Zealand Australia and Poland.

The Patent is still pending in the following countries: Argentina, Canada, Switzerland, Taiwan and  USA.

Type of business relationship sought

Licensing agreements in available countries. In particular APR is interested to evaluate licensing opportunities in countries where the product is approved (Germany) or about to be approved (Switzerland) as well as in all the other countries in Europe (where a MRP is about to start) and outside.

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioTrinity
ShareVault
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us